Dai-ichi Life Insurance Company’s NovoCure NVCR Stock Holding History

Dai-ichi Life Insurance Company’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-6,958	Closed	-$289K	–	485
2023 Q2	$289K	Buy	+6,958	New	+$432K	0.01%	445
2022 Q1	–	Sell	-12,958	Closed	-$973K	–	534
2021 Q4	$973K	Hold	12,958	–	–	0.01%	428
2021 Q3	$1.5M	Buy	12,958 +7,000	+117%	+$1.06M	0.02%	380
2021 Q2	$1.32M	Buy	+5,958	New	+$1.16M	0.02%	398

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Dai-ichi Life Insurance Company's NVCR Position: Q3 2023 in Review

Dai-ichi Life Insurance Company sold out of NovoCure (NVCR) in Q3 2023, closing a stake of 6,958 shares — an estimated $289K sold.

Dai-ichi Life Insurance Company first reported a position in NVCR in Q2 2021 and held it in 4 quarters. The position peaked at $1.5M in Q3 2021. 227 funds tracked by Wall St. Rank hold NVCR as of Q3 2023.

Dai-ichi Life Insurance Company reported no remaining NovoCure position as of Q3 2023 after selling out during the quarter.
Dai-ichi Life Insurance Company sold 6,958 NovoCure shares in Q3 2023, an estimated $289K.
Dai-ichi Life Insurance Company first reported a position in NovoCure in Q2 2021 and held it in 4 quarters.
Dai-ichi Life Insurance Company's NovoCure position peaked at $1.5M in Q3 2021.
227 funds tracked by Wall St. Rank held NovoCure as of Q3 2023.

Based on Dai-ichi Life Insurance Company's 13F filing for Q3 2023, filed 2 Nov 2023.